Low-Dose Abiraterone in Metastatic Castration-Resistant Prostate Cancer

PURPOSEAbiraterone acetate (AA) is approved for prostate cancer at a standard dose of 1,000 mg fasting. Because of a significant food effect, a lower dose (250 mg with food—AA low dose [AALD]) shows similar efficacy at 75% lower cost. In Brazil, 80% of patients rely on the public health care system,...

Full description

Bibliographic Details
Published in:JCO Global Oncology
Main Authors: Julia Belone Lopes, Ana Elisa Sanches, Beatriz de Menezes Dobbert, Lorena Forner, João Pedro Homse Netto, Luiza Fadul, João Daniel Guedes, Fábio Fernandez, Daniel Vilarim Araujo
Format: Article
Language:English
Published: American Society of Clinical Oncology 2025-08-01
Online Access:https://ascopubs.org/doi/10.1200/GO-25-00132

Internet

https://ascopubs.org/doi/10.1200/GO-25-00132

Similar Items